{"id":51996,"date":"2022-12-14T20:02:17","date_gmt":"2022-12-14T19:02:17","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/the-views-of-1500-patient-groups-on-the-pharmaceutical-industry-and-esg-environmental-social-and-governance-researchandmarkets-com\/"},"modified":"2022-12-14T20:02:17","modified_gmt":"2022-12-14T19:02:17","slug":"the-views-of-1500-patient-groups-on-the-pharmaceutical-industry-and-esg-environmental-social-and-governance-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/the-views-of-1500-patient-groups-on-the-pharmaceutical-industry-and-esg-environmental-social-and-governance-researchandmarkets-com\/","title":{"rendered":"The Views of 1,500 Patient Groups on the Pharmaceutical Industry and ESG (Environmental, Social, and Governance) – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Pharma and ESG – The Patient Perspective – The Views of 1,500 Patient Groups”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThis analysis of patient-group opinions on ESG is based on two online surveys.\n<\/p>\n

\nPatient-group familiarity with ESG<\/strong>\n<\/p>\n

\nAlthough the terms ‘environmental, social, and governance’ are far from being universally embedded in the patient experience, or in healthcare culture, recognition of the purpose and definition of ESG is growing slowly among patient groups. 55% of patient groups responding to a 2021 survey stated that they “Did not know” about pharma’s ESG activities (a decrease from the 61% of respondent patient groups stating the same in the 2020 survey).\n<\/p>\n

\nMany of these patient groups feel that pharma companies could do much more to communicate their ESG strategies to patient groups.\n<\/p>\n

\nThe importance of corporate ESG to patient groups<\/strong>\n<\/p>\n

\nOnly a few of the hundreds of commentaries received by the analyst from respondent patient groups describe pharma companies’ ESG activities as currently relevant to patients, and more a way for the industry to attract ethical investment.\n<\/p>\n

\nOther respondent patient groups acknowledge the potential of ESG to support companies’ efforts at building more patient-centric measures of company performance. Such a patient-centric approach could boost a company’s corporate reputation- and perhaps even encourage more growth, they say.\n<\/p>\n

\n“While all companies strive for profit, I think companies that collaborate and ethically\/sustainably contribute to society will be remembered as growing and successful businesses.”<\/em>\n<\/p>\n

\n– National arthritis patient group, Korea\n<\/p>\n

\n“Sustainability; ethical principles; non-political, win-win orientation in business- and, not in the least, patient centricity.”<\/em>\n<\/p>\n

\n– International blood-cancers patient group, Romania\n<\/p>\n

\nPatient-group involvement in defining ESG criteria and assessing company performance at ESG<\/strong>\n<\/p>\n

\nLooking to the future, many patient groups would like pharma companies to improve how they involve patient communities in defining patient-relevant ESG measures. A significant number (140) of respondent patient groups offered their own criteria for pharma’s ESG targets [details provided in the ‘Pharma and ESG – the Patient Perspective’ report]. Already, too, respondent patient groups are proving capable of measuring pharma’s aptitude at ESG.\n<\/p>\n

\n“It is important to consider the environment, social, and governance of a pharmaceutical company, in regards to their reputation or brand, in order to evaluate if they are a good choice to work with.”<\/em>\n<\/p>\n

\n– National skin-conditions patient group, Australia\n<\/p>\n

\n“Our organization assesses the improvement in the provision of healthcare by pharmaceutical companies a lot. That footprint goes beyond developing medicines, vaccines, supplies, and diagnostic tests, to meeting the medical needs that are pressing in the world. A lot of companies perform this work on sustainability and responsibility, but it is not central for them. Finally, we assess the environmental impacts that the companies cause.”<\/em>\n<\/p>\n

\n– National arthritis patient group, Brazil\n<\/p>\n

\n“From an environmental perspective, our group is focused on how the company prioritizes their international efforts to work with the regions on key efforts to minimize and reduce the impacts on the environment, and public declarations of their commitment to help reduce climate change.”<\/em>\n<\/p>\n

\n– National mental-health patient group, Canada\n<\/p>\n

\nThis report examines:<\/strong>\n<\/p>\n